Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Những quyển sách tương tự

• Targeting the cyclin D–cyclin-dependent kinase (CDK)4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions
  Bằng: Spring, Laura, et al.
  Được phát hành: (2016)
• CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
  Bằng: Spring, Laura M., et al.
  Được phát hành: (2019)
• Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database
  Bằng: Mengdi Zhang, et al.
  Được phát hành: (2025-11-01)
• Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors
  Bằng: Tripathy, Debu, et al.
  Được phát hành: (2017)
• Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
  Bằng: Pınar Kubilay Tolunay, et al.
  Được phát hành: (2024-11-01)